Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

Rhea-AI Summary

Predictive Oncology Inc. (NASDAQ: POAI) has announced successful study results demonstrating the long-term stability and viability of over 150,000 cryopreserved patient tumor samples in its proprietary biobank. The study showed 100% concordance in drug response results between original fresh patient sample testing and long-term cryogenically stored tumor material, some preserved for up to 16 years.

This validation is important for predicting patient outcomes, guiding personalized therapies, target validation, and in silico modeling of drug-tumor responses. The company's biobank, containing 150,000+ tumor specimens, 200,000+ pathology slides, and 20 years of actionable data, positions Predictive Oncology as a key player in AI-driven drug discovery. The global biospecimen market, valued at $4.4 billion in 2023, is expected to reach $11.7 billion by 2031, growing at a CAGR of over 13%.

Positive

• 100% concordance in drug response results between fresh and long-term stored samples
• Validated long-term viability of 150,000+ tumor specimens in proprietary biobank
• 20 years of longitudinal patient and drug response data
• Unique position in enabling drug developers to query patient responses before clinical trials
• Capability to build models for accurately predicting patient outcomes

Negative

• None.

Insights

Medical Research Analyst

This study by Predictive Oncology is a significant breakthrough in biobanking and drug discovery. The demonstration of 100% concordance in drug response results between fresh samples and those cryopreserved for up to 16 years is remarkable. This validates the integrity of their 150,000+ tumor specimen biobank, enhancing its value for pharmaceutical research.

The ability to reliably predict patient outcomes using historical samples is a game-changer for personalized medicine and drug development. It allows for more accurate in silico modeling of drug-tumor responses, potentially reducing the time and cost of bringing new cancer treatments to market. This could accelerate the drug discovery process and improve the success rate of clinical trials.

However, it's important to note that while this study focused on ovarian tumor samples, further validation across other cancer types would strengthen these findings. Overall, this development positions Predictive Oncology as a valuable partner for pharmaceutical companies in oncology drug discovery.

Financial Analyst

From a financial perspective, this development significantly enhances Predictive Oncology's market position. The global biospecimen market, valued at $4.4 billion in 2023, is projected to grow at a 13% CAGR, reaching $11.7 billion by 2031. POAI's validated biobank positions them to capture a substantial share of this expanding market.

The company's unique assets - 150,000+ tumor specimens, 200,000 pathology slides and 20 years of drug response data - create a high barrier to entry for competitors. This could lead to increased partnerships with pharmaceutical companies, potentially boosting POAI's revenue streams.

However, investors should consider that while this technology is promising, its full commercial impact may take time to materialize. The company's ability to monetize this asset effectively and manage operational costs will be important for future financial performance. Keep an eye on upcoming quarterly reports for signs of increased partnership deals or revenue growth.

Study further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples

Global biospecimen market valued at $4.4 billion in 2023, expected to grow at an annual CAGR of more than 13%, reaching $11.7 billion by 2031¹

PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced the results of a successful study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples stored within the Company’s proprietary biobank.

Importantly, with more than 20 years of longitudinal patient and drug response data, the study demonstrated that the samples stored in the biobank continue to produce drug response data that is consistent with their original clinical testing results. This is critical for predicting outcomes, most notably overall survival (OS), for guiding personalized therapies, target validation, and in silico modeling of drug-tumor responses.

To successfully demonstrate the reproducibility of drug response results for these biobank samples, a comparative study was executed using previously generated drug responses across a subset of patient ovarian tumor samples maintained in the Company’s biobank. These samples had originally been tested and cryopreserved between 2008 and 2016.

Concordance of drug response results between the original fresh patient sample testing and long-term cryogenically stored tumor material from the same patient was 100%.

“We are extremely pleased with the results of this study, which demonstrates that even after an extended period of time – some as long as 16 years – the samples cryopreserved in our biobank remain viable and able to deliver the same drug response data as when originally tested,” said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery at Predictive Oncology. “This not only validates the utility of our biobank, but also the strength and reliability of the drug response data that we compiled over those many years. We are uniquely positioned to enable drug developers to query patient responses to their drug candidates, accounting for real-world patient heterogeneity, and to validate targets and biomarkers long before human clinical trials commence.”

“Our biobank of more than 150,000 tumor specimens, 200,000 pathology slides, and 20 years of actionable drug and tumor response data represent key assets that are unique to Predictive Oncology,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. “With these capabilities, we can build models capable of accurately predicting patient outcomes, allowing us to play a key role in guiding personalized therapies, and discovering novel biomarkers. The results of this study demonstrate the long-term viability of these tumor samples, underscoring its value not only to Predictive Oncology, but our drug developer partners as well.”

Predictive Oncology also announced today the release of a new white paper that discusses this study, and the importance of tumor sample viability, in greater detail. The white paper can be accessed at: https://predictive-oncology.com/blog/reproducible/

About Predictive Oncology

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s proprietary AI/ML platform has been scientifically validated to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA. 

Investor Relations Contact
Tim McCarthy  
LifeSci Advisors, LLC  
tim@lifesciadvisors.com

Forward-Looking Statements: 
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.

___________________________________
¹ https://www.biospace.com/biospecimen-contract-research-services-market-worth-usd-11-70-billion-to-2031

FAQ

What were the results of Predictive Oncology's (POAI) biobank stability study?

The study demonstrated 100% concordance in drug response results between original fresh patient sample testing and long-term cryogenically stored tumor material, some preserved for up to 16 years. This validates the long-term stability and viability of over 150,000 cryopreserved patient tumor samples in Predictive Oncology's proprietary biobank.

How does the biobank study impact Predictive Oncology's (POAI) drug discovery capabilities?

The study validates the utility of Predictive Oncology's biobank and the reliability of its drug response data. This positions the company to enable drug developers to query patient responses to drug candidates, accounting for real-world patient heterogeneity, and to validate targets and biomarkers before human clinical trials commence.

What is the size and scope of Predictive Oncology's (POAI) biobank as of August 2024?

As of August 2024, Predictive Oncology's biobank contains over 150,000 tumor specimens, more than 200,000 pathology slides, and 20 years of actionable drug and tumor response data. This extensive collection is important for building models capable of accurately predicting patient outcomes and guiding personalized therapies.

What is the projected growth of the global biospecimen market according to Predictive Oncology's (POAI) press release?

According to the press release, the global biospecimen market was valued at $4.4 billion in 2023 and is expected to grow at an annual CAGR of more than 13%, reaching $11.7 billion by 2031.